The Role of K13 in Artemisinin Resistance
Poster May 09, 2018
Artemisinins are a key component of the combination therapy used to treat malaria. Plasmodium falciparum, the causative agent of the most deadly from of malaria is evolving resistance to artemisinins. The decreased effectiveness of artemisinins increases the probability of resistance to the partner drugs as well; risking total treatment failure which would result in thousands more deaths a year. The gene shown to have the largest affect in modulating resistance is K13. Here we present an RNA-seq study on an isogenic mutant with a dysregulated K13 gene that provides evidence that K13 is involved in regulating DNA replication and repair.
Genome-wide association studies (GWAS) have identified more than 100 genetic loci associated with type 2 diabetes. The majority of these are located in the intergenic or intragenic regions suggesting that the implicated variants may alter chromatin conformation. This, in turn, is likely to influence the expression of nearby or more remotely located genes to alter beta cell function. At present, however, detailed molecular and functional analyses are still lacking for most of these variants. We recently analysed one of these loci and mapped five causal variants in an islet-specific enhancer cluster within the STARD10 gene locus. Here, we aimed to understand how these causal variants influence b-cell function by alteration of the chromatin structure of enhancer clusterREAD MORE
Human papillomavirus (HPV) vaccine rates continue to be low in the United States. Young women ages 18-26 years are eligible for catch-up vaccination but previous research shows that relationships status and percieved risk may be barriers to HPV vaccination. The purpose of this quantitative study was to assess the association between relationship status and perceived risk for HPV among young adult women.READ MORE
This abstract discusses three cases of pediatric heart transplant patients who suffered from parvovirus (B19) infection. Of these patients, two ( B & C) responded well to standard intravenous Ig therapy. Patient A however, did not respond to standard treatment and was begun on subcutaneous Ig, which effectively diminished his viral load. Thus, subcutaneous Ig infusions might serve as a second line treatment for transplant patients with parvovirus who do not respond well to the standard approach.READ MORE